Figure 2
From: A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
Serum phosphate per cent change in concentration from baseline in patients doses at 250 mg QD and 300 mg QD.
Figure 2 | British Journal of Cancer
